Aratana Therapeutics,'s Revenue in the fiscal year 2018 $ 35.41 millions
Aratana Therapeutics,'s Revenue in the fiscal year 2017 $ 25.57 millions
Aratana Therapeutics,'s Revenue in the fiscal year 2016 $ 38.55 millions
Aratana Therapeutics,'s Revenue in the fiscal year 2015 $ 0.68 millions
Aratana Therapeutics,'s Revenue in the fiscal year 2014 $ 0.77 millions
PETX Revenue first quarter 2019 Y/Y Growth Comment
Aratana Therapeutics, Inc. reported Revenue surge of 82.18% year on year in the first quarter 2019, to $ 7.36 millions, this is lower than Aratana Therapeutics, Inc.'s recent average Revenue surge of 2124.85%.
Looking into first quarter 2019 results within Major Pharmaceutical Preparations industry 62 other companies have achieved higher Revenue growth. While Aratana Therapeutics, Inc.' s Revenue jump of 82.18% ranks overall at the positon no. 373 in the first quarter 2019.
PETX Revenue ( Y/Y Growth %)
2019
2018
2017
2016
4th Quarter
December
-
-53.06 %
3506.9 %
383.33 %
3rd Quarter
September
-
250 %
15300 %
-82.61 %
2nd Quarter
June
-
-4.84 %
-86.44 %
16443.48 %
1st Quarter
March
82.18 %
6.32 %
2135.29 %
6.25 %
FY
-
38.47 %
-33.64 %
-
Financial Statements
Aratana Therapeutics,'s first quarter 2019 Revenue
Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019
Aratana Therapeutics,'s Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
22020.35 %
1271.64 %
-99.89 %
(Jun 30 2016)
PETX's I. Quarter Q/Q Revenue Comment
Aratana Therapeutics, Inc. achieved in the I. Quarter 2019 below company average Revenue jump of 49.9% quarter on quarter, to $ 7.36 millions.
Although the I. Quarter 2019 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the I. Quarter surge, eclipses the -61.38% growth in the I. Quarter a year ago
Within Major Pharmaceutical Preparations industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Aratana Therapeutics,'s Revenue growth quarter on quarter, overall rank is 256.
Aratana Therapeutics, Inc. achieved in the I. Quarter 2019 below company average Revenue jump of 49.9% quarter on quarter, to $ 7.36 millions.
I. Quarter 2019 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -61.38% in the I. Quarter a year ago.
Within Major Pharmaceutical Preparations industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Aratana Therapeutics,'s Revenue growth quarter on quarter, overall rank is 256.
Aratana Therapeutics,'s 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Mar 31 2019)
12 Months Ending (Dec 31 2018)
12 Months Ending (Sep 30 2018)
12 Months Ending (Jun 30 2018)
12 Months Ending (Mar 31 2018)
Cumulative Revenue 12 Months Ending
$ 38.73
$ 35.41
$ 40.96
$ 25.57
$ 25.82
Y / Y Revenue Growth (TTM)
49.99 %
38.47 %
165.86 %
175.4 %
-38.78 %
Year on Year Revenue Growth Overall
Ranking
# 3603
# 402
# 21
# 2487
# 413
Seqeuential Revenue Change (TTM)
9.37 %
-13.55 %
60.19 %
-0.97 %
0.97 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2637
# 2931
# 67
# 2209
# 459
Cumulative Revenue growth Comment
Although Aratana Therapeutics,'s Annual Revenue growth year on year were below company's average 1751.67% , Revenue announced in the Mar 31 2019 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 49.99% year on year, from 38.47% in Dec 31 2018.
In the Healthcare sector 456 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 402 to 3603.
Although Aratana Therapeutics,'s Annual Revenue growth year on year were below company's average 1751.67% , Revenue announced in the Mar 31 2019 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 49.99% year on year, from 38.47% in Dec 31 2018.
In the Healthcare sector 456 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 402 to 3603.
About Aratana Therapeutics, Revenue Growth Rates (PETX), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
141.94%